研究单位：[1]Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Qilu Hospital of Shandong University[3]People's Hospital of Quzhou[4]Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.
The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer.
